DarioHealth announced new research presented at the Diabetes Technology Society 2023 Meeting on November 7, 2023. The new research demonstrated the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes. The new study examined the blood glucose and walking data of 989 Dario users to understand the impact of integrating clinical and behavioral data in a single digital app-based experience. The results demonstrated significantly reduced blood glucose levels in the first four months of using Dario and increased step levels in the same timeframe maintained for 12 months. In addition, the results demonstrated clinically significant reductions in blood glucose levels in users who tracked at least 400 steps per day. “I believe this new research shows the potential for an integrated digital solution to help people manage their overall health. We are excited to share this new data as another example of how our highly personalized approach to improving behaviors can help people take control of their overall health and realize better results,” said Yifat Hershcovitz, Ph.D., Vice President of Clinical and Scientific Affairs at Dario.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DRIO:
- DarioHealth price target lowered to $5 from $13 at TD Cowen
- DarioHealth price target lowered to $2.50 from $4.10 at Alliance Global Partners
- DarioHealth reports Q3 EPS (49c), consensus (46c)
- DarioHealth Reports Third Quarter 2023 Financial and Operating Results
- DarioHealth launches new smart blood sugar meter for Apple iPhone 15